BiotechTube

robatumumab

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteosarcoma

Conditions

Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor

Trial Timeline

Feb 1, 2008 → Aug 31, 2013

NCT ID
NCT00617890

About robatumumab

robatumumab is a phase 2 stage product being developed by Merck for Osteosarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00617890. Target conditions include Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00617890Phase 2Terminated

Competing Products

18 competing products in Osteosarcoma

See all competitors
ProductCompanyStageHype Score
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
33
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
52
PemetrexedEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
Olaparib + CeralasertibAstraZenecaPhase 2
52
Saracatinib + PlaceboAstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52
pazopanibNovartisPhase 2
52
AvelumabPfizerPhase 2
51
Nivolumab + AzacitidineBristol Myers SquibbPhase 1
32
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
51
Cisplatin liposomalInsmedPhase 1/2
38
CabozantinibIpsenPhase 2
49
Sm-EDTMPJazz PharmaceuticalsPhase 2
49
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).Lantheus HoldingsPhase 1/2
38
REOLYSIN®Oncolytics BiotechPhase 2
44

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85